These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37289136)

  • 21. The National Institute on Aging-Alzheimer's Association research criteria for mild cognitive impairment due to Alzheimer's disease: predicting the outcome.
    Guo LH; Alexopoulos P; Eisele T; Wagenpfeil S; Kurz A; Perneczky R
    Eur Arch Psychiatry Clin Neurosci; 2013 Jun; 263(4):325-33. PubMed ID: 22932720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer's disease.
    Mank A; van Maurik IS; Rijnhart JJM; Bakker ED; Bouteloup V; Le Scouarnec L; Teunissen CE; Barkhof F; Scheltens P; Berkhof J; van der Flier WM
    Alzheimers Res Ther; 2022 Aug; 14(1):110. PubMed ID: 35932034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.
    Vos SJ; Verhey F; Frölich L; Kornhuber J; Wiltfang J; Maier W; Peters O; Rüther E; Nobili F; Morbelli S; Frisoni GB; Drzezga A; Didic M; van Berckel BN; Simmons A; Soininen H; Kłoszewska I; Mecocci P; Tsolaki M; Vellas B; Lovestone S; Muscio C; Herukka SK; Salmon E; Bastin C; Wallin A; Nordlund A; de Mendonça A; Silva D; Santana I; Lemos R; Engelborghs S; Van der Mussele S; ; Freund-Levi Y; Wallin ÅK; Hampel H; van der Flier W; Scheltens P; Visser PJ
    Brain; 2015 May; 138(Pt 5):1327-38. PubMed ID: 25693589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia.
    Morris JC
    Arch Neurol; 2012 Jun; 69(6):700-8. PubMed ID: 22312163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding the role of psychiatrists in the diagnosis and management of mild cognitive impairment and mild Alzheimer's disease dementia: a cross-sectional survey.
    Gopalakrishna G; Brunton S; Pruzin J; Alford S; Hamersky C; Sabharwal A
    BMC Psychiatry; 2023 Oct; 23(1):716. PubMed ID: 37794326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
    Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
    Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
    Podhorna J; Krahnke T; Shear M; Harrison JE;
    Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer's disease patients: a retrospective observational study.
    Scaricamazza E; Colonna I; Sancesario GM; Assogna F; Orfei MD; Franchini F; Sancesario G; Mercuri NB; Liguori C
    Neurol Sci; 2019 Jul; 40(7):1377-1382. PubMed ID: 30903419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA Expression Signature in Mild Cognitive Impairment Due to Alzheimer's Disease.
    De Felice B; Montanino C; Oliva M; Bonavita S; Di Onofrio V; Coppola C
    Mol Neurobiol; 2020 Nov; 57(11):4408-4416. PubMed ID: 32737762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Machine Learning-Based Holistic Approach to Predict the Clinical Course of Patients within the Alzheimer's Disease Spectrum.
    Massetti N; Russo M; Franciotti R; Nardini D; Mandolini GM; Granzotto A; Bomba M; Delli Pizzi S; Mosca A; Scherer R; Onofrj M; Sensi SL; ;
    J Alzheimers Dis; 2022; 85(4):1639-1655. PubMed ID: 34958014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting progression from mild cognitive impairment to Alzheimer's disease on an individual subject basis by applying the CARE index across different independent cohorts.
    Chen J; Chen G; Shu H; Chen G; Ward BD; Wang Z; Liu D; Antuono PG; Li SJ; Zhang Z;
    Aging (Albany NY); 2019 Apr; 11(8):2185-2201. PubMed ID: 31078129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mild cognitive impairment. Part 2: Biological markers for diagnosis and prediction of dementia in Alzheimer's disease.
    Forlenza OV; Diniz BS; Teixeira AL; Stella F; Gattaz W
    Braz J Psychiatry; 2013; 35(3):284-94. PubMed ID: 24142092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Flicker L; Bonfill Cosp X
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012884. PubMed ID: 29164602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease.
    Alexopoulos P; Werle L; Roesler J; Thierjung N; Gleixner LS; Yakushev I; Laskaris N; Wagenpfeil S; Gourzis P; Kurz A; Perneczky R;
    Alzheimers Res Ther; 2016 Dec; 8(1):51. PubMed ID: 27931251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Early detection of Alzheimer's disease and dementia prediction in patients with mild cognitive impairment : Summary of current recommendations].
    Rostamzadeh A; Jessen F
    Nervenarzt; 2020 Sep; 91(9):832-842. PubMed ID: 32300816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neural biomarker diagnosis and prediction to mild cognitive impairment and Alzheimer's disease using EEG technology.
    Jiao B; Li R; Zhou H; Qing K; Liu H; Pan H; Lei Y; Fu W; Wang X; Xiao X; Liu X; Yang Q; Liao X; Zhou Y; Fang L; Dong Y; Yang Y; Jiang H; Huang S; Shen L
    Alzheimers Res Ther; 2023 Feb; 15(1):32. PubMed ID: 36765411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictability of polygenic risk score for progression to dementia and its interaction with APOE ε4 in mild cognitive impairment.
    Pyun JM; Park YH; Lee KJ; Kim S; Saykin AJ; Nho K;
    Transl Neurodegener; 2021 Aug; 10(1):32. PubMed ID: 34465370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment.
    Shen Y; Wang H; Sun Q; Yao H; Keegan AP; Mullan M; Wilson J; Lista S; Leyhe T; Laske C; Rujescu D; Levey A; Wallin A; Blennow K; Li R; Hampel H
    Biol Psychiatry; 2018 Mar; 83(5):447-455. PubMed ID: 28359566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer's disease.
    Pillai JA; Bena J; Bekris L; Kodur N; Kasumov T; Leverenz JB; Kashyap SR;
    Alzheimers Res Ther; 2023 Mar; 15(1):54. PubMed ID: 36927447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.